Our CEO, Kathryn Hayashi, in conversation with Business in Vancouver on the strategic partnership with Canadian Nuclear Laboratories (CNL) for the commercial production of Actinium-225, a rare medical isotope that has the potential to serve as the basis of new ground-breaking cancer treatments.
To hear the podcast please click Here